Activa Deep-Brain Stimulation Coverage Includes Provider, Facility Criteria
This article was originally published in The Gray Sheet
Executive Summary
CMS will monitor results of two long-term clinical studies evaluating "optimal targeting" for deep-brain stimulation to treat Parkinson's disease and essential tremor, following a positive national coverage determination
You may also be interested in...
Deep-Brain Stimulation Curbs Some Parkinson’s Symptoms, Not All – NEJM
Relatively young patients may prove the best candidates for subthalamic nucleus stimulation therapy to treat Parkinson's disease, researchers write in the Nov. 13 issue of The New England Journal of Medicine
Deep-Brain Stimulation Curbs Some Parkinson’s Symptoms, Not All – NEJM
Relatively young patients may prove the best candidates for subthalamic nucleus stimulation therapy to treat Parkinson's disease, researchers write in the Nov. 13 issue of The New England Journal of Medicine
Activa Alternative In Waiting? ANS Taps Deep Brain Stim, Spinal Drug Delivery
Advanced Neuromodulation Systems' deep-brain stimulation device to treat Parkinsonian tremor, nearing pivotal trials, should feature a smaller size and broader programming parameters than Medtronic's Activa DBS, according to the firm